Companies: 10,795·Total market cap: $144.5T
SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc.

SLSNASDAQHealthcare● Active
$7.98
$-0.25(-3.04%)
Market Cap$1.1B
P/E Ratio
52W High$9.51
52W Low$1.39
Overview

SELLAS Life Sciences Group, Inc. (SLS) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

sls · stock forecast · 5 analysts (3M) · FMP · updated Jun 9, 2026

Analyst Rating & Consensus

Based on 5 Wall Street analysts in the past 3 months

SellBuy

Buy

5 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
5
Hold
0
Sell
0
Strong Sell
0
Total: 5 · Buy rate: 100.0%

12-Month Price Target

High

$3.20

Consensus

$2.80

-64.9% upside

Low

$2.40

Median: $2.8 · Last Close: $7.98

The SELLAS Life Sciences Group, Inc. (SLS) analyst consensus is Buy, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month SLS price target is $2.80, representing -64.9% upside from the current price of $7.98.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $3 (-64.9%)

Consensus Target

$2.80

-64.9% upside

High Target

$3.2

-59.9%

Low Target

$2.4

-69.9%

Current Price

$7.98

as of today

Based on analyst price targets, the SLS stock price prediction for the next 12 months ranges from $2.4 to $3.2. The consensus SLS price forecast of $2.80 implies -64.9% upside from the current price of $7.98.

Short-Term Price Prediction

Bull

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-10$8.385.00%

1-day model range: $8.25–$8.51. Peak: $8.51 (+5.00%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$18+120.0%
2028$29+265.2%
2029$40+397.8%
2030$48+497.1%
2031+562.7%
Confidence:MediumCapped at 120% annual limit

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

64%7%29%
9Buy
1Neutral
4Sell
RSI (14)54.4Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · SLS · Jun 9, 2026

Simple Moving Average (SMA)
MA 5$8.35SELL
MA 10$8.60SELL
MA 20$7.84BUY
MA 50$5.99BUY
MA 100$5.26BUY
MA 200$3.67BUY
Current $SLS · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$8.35SELL
EMA 10$8.31SELL
EMA 20$7.77BUY
EMA 50$6.54BUY
EMA 100$5.46BUY
EMA 200$4.26BUY
Current $SLS · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Maxim Group2026-03-12
Maintains
BuyBuy
Maxim Group2025-07-16
Maintains
BuyBuy
Cantor Fitzgerald2023-11-22
Maintains
OverweightOverweight
Cantor Fitzgerald2023-09-07
Maintains
OverweightOverweight
Alliance Global Partners2022-11-15
Maintains
BuyBuy
Cantor Fitzgerald2022-06-28
Maintains
OverweightOverweight
Cantor Fitzgerald2021-07-21
Maintains
OverweightOverweight
Alliance Global Partners2019-11-18
Maintains
BuyBuy
Maxim Group2019-11-18
Maintains
BuyBuy
Maxim Group2019-11-18
Upgrade ↑
HoldBuy

Wall Street analysts have recently issued updated ratings on SELLAS Life Sciences Group, Inc. (SLS) stock. Of the recent 17 rating actions, 3 were upgrades and 0 were downgrades. 5 analysts currently cover SLS.

Analyst Recommendation Trends

Buy ratings11
Hold ratings00
Sell ratings00

SLS analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$36M

↓ 64.5% YoY

Revenue Next Year

$44M

↑ 22.4% YoY

EPS This Year

$-0.21

EPS Next Year

$-0.15

↓ 28.6% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast SLS EPS of $-0.21 for the current fiscal year, based on estimates from 1 analysts. The SLS revenue forecast is $36M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The SLS stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus SLS price target is $2.80 (-64.9% upside), with an analyst consensus of Buy.

The SLS short-term stock prediction for tomorrow is $8.38 (+5.00%). The SLS stock price prediction for 2027 estimates an average of $18. The SLS stock prediction for 2030 projects a range of $40–$56.

SELLAS Life Sciences Group, Inc. trades on NASDAQ under the ticker SLS. The SLS stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

SLS forecast · 8 questions

According to 5 Wall Street analysts, the average 12-month SLS price target is $2.80, with a high forecast of $3.20 and a low of $2.40. The median price target is shown in the chart above when available. This implies -64.9% potential upside from the current price of $7.98.

SLS price targetWhat is SLS price targetSLS analyst price targetSLS 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.